{"id":"https://openalex.org/W6885115362","doi":"https://doi.org/10.26434/chemrxiv.11829102.v1","title":"Potential 2019-nCoV 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches","display_name":"Potential 2019-nCoV 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches","alternate_titles":[],"publication_year":2020,"publication_date":"2020-02-10","ids":{"openalex":"https://openalex.org/W6885115362","doi":"https://doi.org/10.26434/chemrxiv.11829102.v1"},"language":"en","primary_location":{"id":"doi:10.26434/chemrxiv.11829102.v1","doi":"https://doi.org/10.26434/chemrxiv.11829102.v1","is_oa":true,"landing_page_url":"https://doi.org/10.26434/chemrxiv.11829102.v1","pdf_url":"https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/60c7482bee301ce75fc79817/original/potential-2019-n-co-v-3c-like-protease-inhibitors-designed-using-generative-deep-learning-approaches.pdf","source":{"id":"https://openalex.org/S4393918830","display_name":"ChemRxiv","issn_l":"2573-2293","issn":["2573-2293"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},"parent_works":[],"lineage":["https://openalex.org/W6885115362"],"child_works_count":0,"type":"preprint","is_traditional":true,"indexed_in":["crossref","datacite"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/60c7482bee301ce75fc79817/original/potential-2019-n-co-v-3c-like-protease-inhibitors-designed-using-generative-deep-learning-approaches.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Alex Zhavoronkov","orcid":"https://orcid.org/0000-0001-7067-8966","observed_orcids":["https://orcid.org/0000-0001-7067-8966"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alex Zhavoronkov","raw_affiliation_strings":["Insilico Medicine, Hong Kong, China"],"raw_orcid":"https://orcid.org/0000-0001-7067-8966","affiliations":[{"raw_affiliation_string":"Insilico Medicine, Hong Kong, China","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083789823","display_name":"Vladimir Aladinskiy","orcid":"https://orcid.org/0000-0002-3976-3991","observed_orcids":["https://orcid.org/0000-0002-3976-3991"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Vladimir Aladinskiy","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0002-3976-3991","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032823970","display_name":"Alexander Zhebrak","orcid":"https://orcid.org/0000-0003-1905-9996","observed_orcids":["https://orcid.org/0000-0003-1905-9996"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alexander Zhebrak","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0003-1905-9996","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036803601","display_name":"Bogdan A. Zagribelnyy","orcid":"https://orcid.org/0000-0003-3799-2720","observed_orcids":["https://orcid.org/0000-0003-3799-2720"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bogdan Zagribelnyy","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0003-3799-2720","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061831662","display_name":"Victor A. Terentiev","orcid":"https://orcid.org/0000-0001-7799-9383","observed_orcids":["https://orcid.org/0000-0001-7799-9383"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Victor Terentiev","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0001-7799-9383","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5136589087","display_name":"Dmitry Bezrukov","orcid":"https://orcid.org/0000-0002-3173-2146","observed_orcids":["https://orcid.org/0000-0002-3173-2146"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Dmitry S. Bezrukov","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0002-3173-2146","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061298160","display_name":"Daniil A. Polykovskiy","orcid":"https://orcid.org/0000-0002-0899-8368","observed_orcids":["https://orcid.org/0000-0002-0899-8368"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Daniil Polykovskiy","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0002-0899-8368","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077492338","display_name":"Rim Shayakhmetov","orcid":"https://orcid.org/0000-0001-5425-9964","observed_orcids":["https://orcid.org/0000-0001-5425-9964"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Rim Shayakhmetov","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0001-5425-9964","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002765647","display_name":"Andrey Filimonov","orcid":"https://orcid.org/0000-0001-9897-0467","observed_orcids":["https://orcid.org/0000-0001-9897-0467"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andrey Filimonov","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0001-9897-0467","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Philipp Orekhov","orcid":"https://orcid.org/0000-0003-4078-4762","observed_orcids":["https://orcid.org/0000-0003-4078-4762"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Philipp Orekhov","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0003-4078-4762","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Yilin Yan","orcid":"https://orcid.org/0000-0002-2186-8592","observed_orcids":["https://orcid.org/0000-0002-2186-8592"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yilin Yan","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0002-2186-8592","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084087860","display_name":"Olga V. Popova","orcid":"https://orcid.org/0000-0001-6004-9752","observed_orcids":["https://orcid.org/0000-0001-6004-9752"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Olga Popova","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0001-6004-9752","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063636725","display_name":"Quentin Vanhaelen","orcid":"https://orcid.org/0000-0002-4611-2046","observed_orcids":["https://orcid.org/0000-0002-4611-2046"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Quentin Vanhaelen","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0002-4611-2046","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113161674","display_name":"Alex Aliper","orcid":"https://orcid.org/0000-0002-4363-0710","observed_orcids":["https://orcid.org/0000-0002-4363-0710"]},"institutions":[{"id":"https://openalex.org/I4405259654","display_name":"3D Medicines, Inc. (China)","ror":"https://ror.org/02grx1t29","country_code":"CN","type":"company","lineage":["https://openalex.org/I4405259654"]}],"countries":["CN"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alex Aliper","raw_affiliation_strings":["Insilico Medicine Hong Kong Ltd , 307A , E1 ,"],"raw_orcid":"https://orcid.org/0000-0002-4363-0710","affiliations":[{"raw_affiliation_string":"Insilico Medicine Hong Kong Ltd , 307A , E1 ,","institution_ids":["https://openalex.org/I4405259654"]}]},{"author_position":"last","author":{"id":null,"display_name":"Yan Ivanenkov","orcid":"https://orcid.org/0000-0002-8968-0879","observed_orcids":["https://orcid.org/0000-0002-8968-0879"]},"institutions":[{"id":"https://openalex.org/I2800906782","display_name":"Hong Kong Science and Technology Parks Corporation","ror":"https://ror.org/05q8mqd91","country_code":"HK","type":"nonprofit","lineage":["https://openalex.org/I2800906782"]}],"countries":["HK"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Yan Ivanenkov","raw_affiliation_strings":["Hong Kong Science and Technology Park , Pak Shek Kok , New Territories , Hong Kong"],"raw_orcid":"https://orcid.org/0000-0002-8968-0879","affiliations":[{"raw_affiliation_string":"Hong Kong Science and Technology Park , Pak Shek Kok , New Territories , Hong Kong","institution_ids":["https://openalex.org/I2800906782"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":118,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.9965999722480774,"subfield":{"id":"https://openalex.org/subfields/3002","display_name":"Drug Discovery"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12576","display_name":"vaccines and immunoinformatics approaches","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sars-cov-2","display_name":"SARS-CoV-2","score":0.9779999852180481},{"id":"https://openalex.org/keywords/3c-like-protease","display_name":"3C-like protease","score":0.953000009059906},{"id":"https://openalex.org/keywords/mpro-inhibitors","display_name":"Mpro inhibitors","score":0.875},{"id":"https://openalex.org/keywords/generative-deep-learning","display_name":"generative deep learning","score":0.8320000171661377},{"id":"https://openalex.org/keywords/drug-design","display_name":"drug design","score":0.5680000185966492},{"id":"https://openalex.org/keywords/homology-modeling","display_name":"homology modeling","score":0.8149999976158142},{"id":"https://openalex.org/keywords/lopinavir","display_name":"lopinavir","score":0.734000027179718},{"id":"https://openalex.org/keywords/antiviral-drug-discovery","display_name":"antiviral drug discovery","score":0.8209999799728394}],"concepts":[{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.7039999961853027},{"id":"https://openalex.org/C108583219","wikidata":"https://www.wikidata.org/wiki/Q197536","display_name":"Deep learning","level":2,"score":0.661300003528595},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.5012999773025513},{"id":"https://openalex.org/C2776401178","wikidata":"https://www.wikidata.org/wiki/Q12050496","display_name":"Feature (linguistics)","level":2,"score":0.35690000653266907},{"id":"https://openalex.org/C50644808","wikidata":"https://www.wikidata.org/wiki/Q192776","display_name":"Artificial neural network","level":2,"score":0.29989999532699585},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.28690001368522644},{"id":"https://openalex.org/C2776714187","wikidata":"https://www.wikidata.org/wiki/Q212410","display_name":"Protease","level":3,"score":0.2727000117301941},{"id":"https://openalex.org/C153180895","wikidata":"https://www.wikidata.org/wiki/Q7148389","display_name":"Pattern recognition (psychology)","level":2,"score":0.2605000138282776},{"id":"https://openalex.org/C119857082","wikidata":"https://www.wikidata.org/wiki/Q2539","display_name":"Machine learning","level":1,"score":0.257999986410141},{"id":"https://openalex.org/C2781067378","wikidata":"https://www.wikidata.org/wiki/Q17027399","display_name":"Interpretability","level":2,"score":0.2547000050544739}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.26434/chemrxiv.11829102.v1","doi":"https://doi.org/10.26434/chemrxiv.11829102.v1","is_oa":true,"landing_page_url":"https://doi.org/10.26434/chemrxiv.11829102.v1","pdf_url":"https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/60c7482bee301ce75fc79817/original/potential-2019-n-co-v-3c-like-protease-inhibitors-designed-using-generative-deep-learning-approaches.pdf","source":{"id":"https://openalex.org/S4393918830","display_name":"ChemRxiv","issn_l":"2573-2293","issn":["2573-2293"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},{"id":"doi:10.13140/rg.2.2.29899.54569","doi":"https://doi.org/10.13140/rg.2.2.29899.54569","is_oa":false,"landing_page_url":"https://doi.org/10.13140/rg.2.2.29899.54569","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"article-journal"}],"best_oa_location":{"id":"doi:10.26434/chemrxiv.11829102.v1","doi":"https://doi.org/10.26434/chemrxiv.11829102.v1","is_oa":true,"landing_page_url":"https://doi.org/10.26434/chemrxiv.11829102.v1","pdf_url":"https://chemrxiv.org/engage/api-gateway/chemrxiv/assets/orp/resource/item/60c7482bee301ce75fc79817/original/potential-2019-n-co-v-3c-like-protease-inhibitors-designed-using-generative-deep-learning-approaches.pdf","source":{"id":"https://openalex.org/S4393918830","display_name":"ChemRxiv","issn_l":"2573-2293","issn":["2573-2293"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8048999905586243}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320309480","display_name":"Nvidia","ror":"https://ror.org/03jdj4y14"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W6885115362.pdf","grobid_xml":"https://content.openalex.org/works/W6885115362.grobid-xml"},"referenced_works_count":44,"referenced_works":["https://openalex.org/W1031578623","https://openalex.org/W2008428711","https://openalex.org/W2034021926","https://openalex.org/W2059174340","https://openalex.org/W2061256139","https://openalex.org/W2062110365","https://openalex.org/W2096541451","https://openalex.org/W2108018232","https://openalex.org/W2129434797","https://openalex.org/W2161572568","https://openalex.org/W2171291163","https://openalex.org/W2171353131","https://openalex.org/W2195009776","https://openalex.org/W2397757171","https://openalex.org/W2470646526","https://openalex.org/W2524827175","https://openalex.org/W2567534979","https://openalex.org/W2718090702","https://openalex.org/W2736137960","https://openalex.org/W2768181348","https://openalex.org/W2789074794","https://openalex.org/W2793945656","https://openalex.org/W2804822363","https://openalex.org/W2805002767","https://openalex.org/W2807209585","https://openalex.org/W2891868449","https://openalex.org/W2894996849","https://openalex.org/W2909194930","https://openalex.org/W2924802096","https://openalex.org/W2952758360","https://openalex.org/W2971690404","https://openalex.org/W3000771439","https://openalex.org/W3001118548","https://openalex.org/W3001449808","https://openalex.org/W3001897055","https://openalex.org/W3003154936","https://openalex.org/W3004280078","https://openalex.org/W3004375400","https://openalex.org/W3006049090","https://openalex.org/W3008394341","https://openalex.org/W4246123830","https://openalex.org/W4248175757","https://openalex.org/W4252198827","https://openalex.org/W4366825477"],"related_works":["https://openalex.org/W4206579729","https://openalex.org/W4230556746","https://openalex.org/W3121462455","https://openalex.org/W3090171308","https://openalex.org/W3005503699","https://openalex.org/W3206402375","https://openalex.org/W4381996511","https://openalex.org/W4281557787","https://openalex.org/W7132149928","https://openalex.org/W4389380361"],"abstract_inverted_index":{"The":[0],"emergence":[1],"of":[2,22,30,49,58,81,113,123,134],"the":[3,31,38,43,50,66,79,88,176,180,192],"2019":[4],"novel":[5,25,120],"coronavirus":[6],"(2019-nCoV),":[7],"for":[8,24,41,65],"which":[9,42],"there":[10],"is":[11,37,46,91,182],"no":[12],"vaccine":[13],"or":[14],"any":[15],"known":[16,59],"effective":[17],"treatment":[18],"created":[19],"a":[20,111],"sense":[21],"urgency":[23],"drug":[26,56],"discovery":[27],"approaches.":[28],"One":[29],"most":[32],"important":[33],"2019-nCoV":[34,124],"protein":[35],"targets":[36],"3C-like":[39,89],"protease":[40,85,90],"crystal":[44],"structure":[45],"known.":[47],"Most":[48],"immediate":[51],"efforts":[52],"are":[53,158],"focused":[54],"on":[55,102,128],"repurposing":[57],"clinically-approved":[60],"drugs":[61],"and":[62,125,148,163,173],"virtual":[63],"screening":[64],"molecules":[67,169],"available":[68],"from":[69],"chemical":[70],"libraries":[71],"that":[72],"may":[73],"not":[74],"work":[75],"well.":[76],"For":[77],"example,":[78],"IC50":[80],"lopinavir,":[82],"an":[83,96],"HIV":[84],"inhibitor,":[86],"against":[87],"approximately":[92],"50":[93],"micromolar.":[94],"In":[95],"attempt":[97],"to":[98,109,118,185],"address":[99],"this":[100],"challenge,":[101],"January":[103,129],"28th,":[104],"2020":[105],"Insilico":[106],"Medicine":[107],"decided":[108],"utilize":[110],"part":[112],"its":[114,135],"generative":[115,138],"chemistry":[116,139],"pipeline":[117],"design":[119],"drug-like":[121],"inhibitors":[122],"started":[126],"generation":[127],"30th.":[130],"It":[131],"utilized":[132],"three":[133],"previously":[136],"validated":[137],"approaches:":[140],"crystal-derived":[141],"pocked-":[142],"based":[143],"generator,":[144],"homology":[145],"modelling-based":[146],"generation,":[147],"ligand-based":[149],"generation.":[150],"Novel":[151],"druglike":[152],"compounds":[153],"generated":[154],"using":[155,175],"these":[156],"approaches":[157],"being":[159],"published":[160,193],"at":[161],"www.insilico.com/ncov-sprint/":[162],"will":[164,170],"be":[165,171],"continuously":[166],"updated.":[167],"Several":[168],"synthesized":[172],"tested":[174],"internal":[177],"resources;":[178],"however,":[179],"team":[181],"seeking":[183],"collaborations":[184],"synthesize,":[186],"test,":[187],"and,":[188],"if":[189],"needed,":[190],"optimize":[191],"molecules.":[194]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W6885115362","counts_by_year":[{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":10},{"year":2021,"cited_by_count":37},{"year":2020,"cited_by_count":59}],"updated_date":"2026-11-19T14:11:59.513116","created_date":"2025-10-10T00:00:00"}
